77,733 Shares in American Well Co. (NYSE:AMWL) Acquired by Takeda Pharmaceutical Co. Ltd.

Takeda Pharmaceutical Co. Ltd. bought a new position in American Well Co. (NYSE:AMWL - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 77,733 shares of the company's stock, valued at approximately $564,000. American Well makes up about 2.1% of Takeda Pharmaceutical Co. Ltd.'s portfolio, making the stock its 6th largest holding. Takeda Pharmaceutical Co. Ltd. owned about 0.51% of American Well as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in AMWL. HighTower Advisors LLC purchased a new position in shares of American Well during the 3rd quarter valued at $355,000. Walleye Capital LLC purchased a new position in American Well in the third quarter valued at about $167,000. PDT Partners LLC acquired a new position in American Well in the 3rd quarter worth about $107,000. BNP Paribas Financial Markets purchased a new stake in shares of American Well during the 3rd quarter worth about $95,000. Finally, Compagnie Lombard Odier SCmA acquired a new stake in shares of American Well during the 4th quarter valued at about $45,000. Hedge funds and other institutional investors own 56.05% of the company's stock.

American Well Stock Performance

Shares of AMWL traded down $0.11 during mid-day trading on Monday, hitting $7.72. The company's stock had a trading volume of 5,429 shares, compared to its average volume of 101,993. The stock's 50-day moving average is $9.93 and its two-hundred day moving average is $9.32. The firm has a market capitalization of $120.43 million, a PE ratio of -0.55 and a beta of 1.18. American Well Co. has a one year low of $5.00 and a one year high of $17.17.

Remove Ads

American Well (NYSE:AMWL - Get Free Report) last posted its quarterly earnings results on Wednesday, February 12th. The company reported ($2.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.04) by $0.27. American Well had a negative net margin of 81.83% and a negative return on equity of 56.73%. Analysts expect that American Well Co. will post -9.34 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have issued reports on AMWL. Stifel Nicolaus lifted their target price on shares of American Well from $9.00 to $10.00 and gave the company a "hold" rating in a research note on Thursday, February 13th. Needham & Company LLC reiterated a "hold" rating on shares of American Well in a report on Thursday, February 13th. Truist Financial raised their target price on American Well from $10.00 to $12.00 and gave the company a "hold" rating in a report on Friday, February 14th. Wells Fargo & Company raised American Well from an "equal weight" rating to an "overweight" rating and set a $15.00 price objective on the stock in a report on Monday, January 13th. Finally, Morgan Stanley dropped their price target on shares of American Well from $20.00 to $10.50 and set an "equal weight" rating on the stock in a research report on Tuesday, December 17th. Five investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat.com, American Well presently has an average rating of "Hold" and an average price target of $11.90.

Insider Activity at American Well

In related news, insider Phyllis Gotlib sold 4,781 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $8.80, for a total value of $42,072.80. Following the completion of the transaction, the insider now owns 147,998 shares of the company's stock, valued at $1,302,382.40. This represents a 3.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last ninety days, insiders sold 5,219 shares of company stock worth $46,454. 12.80% of the stock is owned by corporate insiders.

American Well Company Profile

American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Converge, a cloud-based platform that enables health providers, payers, and innovators to provide in-person, virtual and automated care; and delivers virtual primary care, post-discharge follow-up, chronic condition management, virtual nursing, e-sitting, on-demand and scheduled virtual visits, specialty consults, automated care, and behavioral health, as well as specialty care programs, including dermatology, musculoskeletal care, second opinion, and cardiometabolic care to patients and members.